Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial

W. J. Sandborn*, B. E. Sands, D. C. Wolf, J. F. Valentine, M. Safdi, S. Katz, K. L. Isaacs, L. D. Wruble, J. Katz, D. H. Present, E. V. Loftus, F. Graeme-Cook, D. J. Odenheimer, S. B. Hanauer

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Fingerprint

Dive into the research topics of 'Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

INIS